University Hospital Basel, Clinic of Urology
Basel, 4056, Switzerland
NCT Number: NCT03068689
"Remote Ischaemic PreConditioning" (RIPC) is performed prior to partial nephrectomy. Postoperative calprotectin dynamics and Blood Oxygen-Level-Dependent (BOLD) MRI are used to to demonstrate the potential renoprotective effect of RIPC
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Not applicable
Basel, 4056, Switzerland
Partial nephrectomy represents the gold standard in organ sparing kidney surgery. Cold ischaemia prevents major bleeding but can yet be associated with impaired kidney function due to reperfusion injury to the tubuli.
Patients undergoing partial nephrectomy (any surgical technique, open, retroperitoneoscopic, transperitoneal, Da Vinci assisted) will be treated with "Remote Ischaemic PreConditioning" (RIPC). RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level. Several studies already demonstrated the reno- and cardioprotective potential of "Remote Ischaemic PreConditioning" (RIPC). It was shown that urinary calprotectin can be used to monitor tubular damage after nephron sparing surgery. Postoperative calprotectin dynamics will be monitored in order to demonstrate the potential renoprotective effect of RIPC. Additionally a BOLD MRI will be performed to to visualize ischemia/reperfusion injury.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
Placebo
Time frame: Baseline, 5 days and 3 months
The study seeks primarily to determine the reduction of the biomarker concentration (Calprotectin and NGAL) in urine. Change in biomarkers will be measured at baseline, during 5 days after surgery and at timepoint month 3.
Time frame: Baseline, 5 days, 3 Months
The secondary objective is to demonstrate the effect/reduction acute renal failure after RIPC as compared to the control group.
Number of patients with acute renal failure will be compared between both groups.
Acute renal failure will be assessed in the days after surgery (acute kidney failure)
Time frame: Baseline, 3 Months
Number of patients with chronic renal failure will be compared between both groups.
Chronic renal failure will be assessed in at baseline until timepoint month 3 (chronic kidney failure).
Time frame: Baseline, day 2
Δ R2*-values in BOLD magnetic resonance tomography (MRT) will be compared between both groups.
University Hospital, Basel, Switzerland
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04924985
Cardiovascular Diseases, Ischemia
New York, United States
View Trial DetailsNCT07422636
Acute Ischemic Stroke, Animal Diseases
Florence, Italy
View Trial DetailsNCT07391709
Cardiovascular Diseases, Genital Diseases
Trabzon, Turkey (Türkiye)
View Trial DetailsNCT02812901
Cardiovascular Diseases, Heart Diseases
Lille, France
View Trial Details